RDNT trades 14.5% above Wall Street's consensus target of $65.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RDNT achieves its forward estimates and maintains a stable P/E multiple of 147.8x. This scenario reflects the blended consensus of 11 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, RadNet, Inc. (RDNT) has a Wall Street consensus price target of $65.00, based on estimates from 11 covering analysts. With the stock currently trading at $76.00, this represents a potential downside of -14.5%. The company has a market capitalization of $5.98B.
Analyst price targets range from a low of $65.00 to a high of $65.00, representing a 0% spread in expectations. The median target of $65.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RDNT trades at a trailing P/E of -283.4x and forward P/E of 147.8x. Analysts expect EPS to grow +291.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SMIDSmith-Midland Corporation | $139M | $26.11 | — | — | — | — | — |
 USPHU.S. Physical Therapy, Inc. | $1.5B | $99.49 | $90.00 | -9.5% | Buy | 34.9x | 13 |
 AMSFAMERISAFE, Inc. | $366M | $19.59 | $33.50 | +71.0% | Buy | 10.4x | 6 |
 AORTArtivion, Inc. | $981M | $20.21 | $35.33 | +74.8% | Buy | — | 12 |
 UHSUniversal Health Services, Inc. | $11.8B | $195.50 | $193.13 | -1.2% | Hold | 8.7x | 44 |
 HCAHCA Healthcare, Inc. | $107.2B | $494.99 | $463.12 | -6.4% | Buy | 16.4x | 46 |
 THCTenet Healthcare Corporation | $24.4B | $283.33 | $289.00 | +2.0% | Buy | 12.6x | 32 |
 CYHCommunity Health Systems, Inc. | $312M | $2.21 | $2.94 | +33.0% | Hold | — | 37 |
 SGRYSurgery Partners, Inc. | $3.0B | $23.20 | $23.50 | +1.3% | Buy | 65.4x | 23 |
 OPCHOption Care Health, Inc. | $5.0B | $31.65 | $28.31 | -10.6% | Hold | 16.8x | 16 |
Quick answers to the most common questions about buying RDNT stock.
RDNT's consensus price target is $65, -14.5% below the current price of $76. The 11 analysts tracking RDNT see downside risk at present valuations.
RDNT has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $65 implies -14.5% downside from current levels.
At a forward P/E of 147.7737x, RDNT trades at a premium valuation. The consensus price target of $65 (-14.5% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $65 for RDNT, while the most conservative target is $65. The consensus of $65 represents the median expectation. These targets typically reflect 12-month expectations.
RDNT is moderately covered, with 11 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 8 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RDNT stock forecast based on 11 Wall Street analysts shows a consensus price target of $65, with estimates ranging from $65 (bear case) to $65 (bull case). The median consensus rating is "Buy".
RDNT trades at a forward P/E ratio of 147.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on RDNT, with 0 Sell ratings and a price target of $65 (-14.5% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RDNT analyst price targets range from $65 to $65, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $65 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.